What does “misbranded” mean in an FDA letter?

Short answer · as of 2026-10-05

In the FD&C Act a drug is misbranded for reasons such as labeling that is false or misleading in any particular (section 502(a)), labeling without adequate directions for use (502(f)(1)), or false or misleading advertising or promotion of a compounded drug (502(bb)). The GLP-1 telehealth letters cite misbranding provisions. The research-use-only letters mainly cite the unapproved-new-drug sections. These are FDA's allegations.

By Peptide Industry Gossip · Published · General explanation, not legal or medical advice. Disclaimer.

Three provisions that appear in letters

  • Section 502(a), 21 U.S.C. 352(a): a drug is misbranded if its labeling is false or misleading in any particular.
  • Section 502(f)(1), 21 U.S.C. 352(f)(1): a drug is misbranded unless its labeling bears adequate directions for use.
  • Section 502(bb), 21 U.S.C. 352(bb): a drug is misbranded if the advertising or promotion of a compounded drug is false or misleading in any particular. It concerns advertising and promotion, not labeling in general.

Where we have seen it

FDA's Sept. 9, 2025 letter to Hims & Hers cites sections 502(a) and 502(bb) over claims it said falsely or misleadingly implied a compounded product equals an approved drug. See our explainer on the GLP-1 letters. The Xcel, Pinnacle and Wholesale Peptide letters in our index cite sections 301(d) and 505(a) instead, which is the unapproved-new-drug route.

What it does not mean

  • Misbranded in the statute is a legal category about labeling and advertising. It does not by itself say a product is contaminated or counterfeit.
  • A warning letter alleging misbranding is not a court finding.
  • We read the statute through the Legal Information Institute. Check the full text and its paragraph numbering before relying on a citation.

Sources

Quotes are from the FDA documents above, retrieved Oct. 5, 2026. FDA can revise those pages. See something wrong? Request a correction.

Related